Spravato is owned by Janssen Pharms.

Spravato contains Esketamine Hydrochloride.

Spravato has a total of 6 drug patents out of which 0 drug patents have expired.

Spravato was authorised for market use on 05 March, 2019.

Spravato is available in spray;nasal dosage forms.

Spravato can be used as treatment of trd in conjunction with an oral antidepressant by nasally administering 56mg or 84mg of esketamine in a maintenance phase weekly or 1x every two weeks to adults who have been administered esketamine in a induction phase for about 4 weeks, treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84 mg of esketamine 2x weekly for 4 weeks in conjunction with an oral antidepressant; treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase in conjunction with an oral antidepressent; treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase followed by a maintenance phase of 56mg or 84 mg weekly or 1x every two weeks in conjunction with an oral antidepressant, treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition twice per week in conjunction with an oral antidepressant; treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine twice per week as a pharmaceutical composition in conjunction with an oral antidepressant; treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition in conjunction with an oral antidepressant, treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase in conjunction with an oral antidepressent; treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase followed by a maintenance phase of 56mg or 84 mg weekly or 1x every two weeks in conjunction with an oral antidepressant; treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84 mg of esketamine 2x weekly for 4 weeks in conjunction with an oral antidepressant, treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant.

The generics of Spravato are possible to be released after 10 September, 2035.